ZA865975B - Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues - Google Patents

Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues

Info

Publication number
ZA865975B
ZA865975B ZA865975A ZA865975A ZA865975B ZA 865975 B ZA865975 B ZA 865975B ZA 865975 A ZA865975 A ZA 865975A ZA 865975 A ZA865975 A ZA 865975A ZA 865975 B ZA865975 B ZA 865975B
Authority
ZA
South Africa
Prior art keywords
disubstituted
amino
acid residues
renin inhibitors
hydroxypentanoic acid
Prior art date
Application number
ZA865975A
Other languages
English (en)
Inventor
Jasjit Singh Bindra
Edward Fox Kleinman
Robert Louis Rosati
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA865975B publication Critical patent/ZA865975B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/86Renin inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA865975A 1985-08-09 1986-08-08 Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues ZA865975B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76416885A 1985-08-09 1985-08-09

Publications (1)

Publication Number Publication Date
ZA865975B true ZA865975B (en) 1988-03-30

Family

ID=25069874

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA865975A ZA865975B (en) 1985-08-09 1986-08-08 Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues

Country Status (3)

Country Link
US (1) US4948913A (de)
DD (1) DD257391A5 (de)
ZA (1) ZA865975B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286897A (en) * 1990-12-28 1994-02-15 Ajinomoto Co., Inc. N-t-butyloxycarbonyl-3-cyclohexyl-L-alanine methyl ester in crystalline form
EP0493087B1 (de) * 1990-12-28 1996-03-13 Ajinomoto Co., Inc. Verfahren zur Kristallisierung von N-t-Butoxycarbonyl-3-cyclohexyl-L-alaninmethylester

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487963A (en) * 1983-01-03 1984-12-11 Merck & Co., Inc. Enantioselective synthesis of 4-amino-3-hydroxy-2,4-(disubstituted)pentanoic acid
FR2590894B1 (fr) * 1985-12-02 1988-09-02 Sanofi Sa Derives d'acide amino-4 butanoique, leur procede de preparation et leur utilisation
JPH0772167B2 (ja) * 1986-09-04 1995-08-02 サントリー株式会社 4―アミノ―3―ヒドロキシ酪酸誘導体の製法

Also Published As

Publication number Publication date
US4948913A (en) 1990-08-14
DD257391A5 (de) 1988-06-15

Similar Documents

Publication Publication Date Title
GB2184730B (en) Ureido renin inhibitors
IL88273A0 (en) Renin inhibitors
GR862276B (en) Improved process for tetrafluorobenzoic acid
GB8322414D0 (en) Renin inhibitors
GR871770B (en) Renin inhibitors
AU7079887A (en) N, s containing corrosion inhibitors
GR862032B (en) Dopamine-b-hydroxylase inhibitors
PH24655A (en) Renin inhibitors iii
PH21776A (en) Dopamine-b-hydroxylase inhibitors
SG39791G (en) Corrosion inhibitors
ZA866061B (en) Process for tetrafluorobenzoic acid
ZA865975B (en) Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
GB2173183B (en) Scale inhibitors
ZA879030B (en) Renin inhibitors iii
ZA868234B (en) Dopamine-beta-hydroxylase inhibitors
YU115086A (en) Process for obtaining new benzamides
PT81973A (en) Dopamine-beta-hydroxylase inhibitors
IE873186L (en) Renin inhibitors iv
IE873034L (en) Renin inhibitors containing phenylalanyl-histidine¹replacements
HUT42704A (en) Anhydrous agent for sun-bathing
GB8606284D0 (en) Scale inhibitors
CS871386A1 (en) Corrosion inhibitor for acid atmospheres
ZA888239B (en) Renin inhibitors
IE873185L (en) Renin inhibitors iii
GB8527336D0 (en) Acid gas removal